Moors & Cabot Inc. decreased its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 8.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,550 shares of the biopharmaceutical company’s stock after selling 1,000 shares during the quarter. Moors & Cabot Inc.’s holdings in Amicus Therapeutics were worth $160,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of FOLD. Dimensional Fund Advisors LP increased its holdings in Amicus Therapeutics by 374.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,098,083 shares of the biopharmaceutical company’s stock valued at $10,518,000 after buying an additional 866,793 shares during the period. Sofinnova Investments Inc. increased its holdings in Amicus Therapeutics by 51.3% in the 4th quarter. Sofinnova Investments Inc. now owns 674,636 shares of the biopharmaceutical company’s stock valued at $6,462,000 after buying an additional 228,667 shares during the period. Xact Kapitalforvaltning AB increased its holdings in Amicus Therapeutics by 15.7% in the 4th quarter. Xact Kapitalforvaltning AB now owns 33,841 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 4,600 shares during the period. Emory University increased its holdings in Amicus Therapeutics by 7.5% in the 4th quarter. Emory University now owns 217,874 shares of the biopharmaceutical company’s stock valued at $2,087,000 after buying an additional 15,148 shares during the period. Finally, Rhumbline Advisers increased its holdings in Amicus Therapeutics by 48.0% in the 4th quarter. Rhumbline Advisers now owns 252,354 shares of the biopharmaceutical company’s stock valued at $2,418,000 after buying an additional 81,792 shares during the period.

In other Amicus Therapeutics news, CEO John F. Crowley sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $13.51, for a total transaction of $270,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jay Barth sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, April 5th. The stock was sold at an average price of $14.20, for a total transaction of $710,000.00. Following the sale, the insider now directly owns 179,767 shares in the company, valued at $2,552,691.40. The disclosure for this sale can be found here. Insiders have sold a total of 180,000 shares of company stock worth $2,401,200 over the last three months. Insiders own 2.90% of the company’s stock.

Shares of Amicus Therapeutics stock opened at $12.18 on Friday. The company has a market cap of $2.81 billion, a P/E ratio of -9.16 and a beta of 1.79. The company has a debt-to-equity ratio of 0.45, a quick ratio of 7.21 and a current ratio of 7.33. Amicus Therapeutics, Inc. has a 1 year low of $8.27 and a 1 year high of $17.62.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.09). The company had revenue of $34.00 million for the quarter, compared to the consensus estimate of $37.82 million. Amicus Therapeutics had a negative net margin of 386.18% and a negative return on equity of 64.11%. The firm’s revenue was up 103.6% on a year-over-year basis. Equities research analysts forecast that Amicus Therapeutics, Inc. will post -1.33 EPS for the current year.

Several equities research analysts recently issued reports on the stock. BidaskClub lowered shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Cantor Fitzgerald set a $20.00 price target on shares of Amicus Therapeutics and gave the company a “buy” rating in a report on Wednesday, May 8th. Zacks Investment Research raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. Robert W. Baird set a $20.00 price target on shares of Amicus Therapeutics and gave the company a “buy” rating in a report on Monday, April 22nd. Finally, Janney Montgomery Scott assumed coverage on shares of Amicus Therapeutics in a report on Friday, April 5th. They set a “buy” rating and a $13.91 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $18.19.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/moors-cabot-inc-has-160000-holdings-in-amicus-therapeutics-inc-fold/3022760.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Recommended Story: Index Funds

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.